A Novel Dendritic Mesoporous Silica Based Sustained Hydrogen Sulfide Donor for the Alleviation of Adjuvant-induced Inflammation in Rats

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2021 Jun 1

PMID 34060389

Citations 6

Authors

Yue Yu

Zhou Wang

Qinyan Yang

Qian Ding

Ran Wang

Zhaoyi Li

Yudong Fang

Junyi Liao

Wei Qi

Keyuan Chen

Meng Li

Yi Zhun Zhu

Affiliations

Soon will be listed here.

Abstract

Purpose: S-propargyl-cysteine (SPRC), an excellent endogenous hydrogen sulfide (HS) donor, could elevate HS levels via the cystathionine γ-lyase CSE)/HS pathway both and . However, the immediate release of HS and daily administration of SPRC potentially limited its clinical use.

Methods: To solve the fore-mentioned problem, in this study, the dendritic mesoporous silica nanoparticles (DMSN) was firstly prepared, and a sustained HS delivery system consisted of SPRC and DMSN (SPRC@DMSN) was then constructed. Their release profiles, both and , were investigated, and their therapeutical effect toward adjuvant-induced arthritis (AIA) rats was also studied.

Results: The spherical morphology of DMSN could be observed under scanning Electron Microscope (SEM), and the transmission electron microscope (TEM) images showed a central-radiational pore channel structure of DMSN. DMSN showed excellent SPRC loading capacity and attaining a sustained releasing ability than SPRC both and , and the prolonged SPRC releasing could further promote the release of HS in a sustained manner through CSE/HS pathway both and . Importantly, the SPRC@DMSN showed promising anti-inflammation effect against AIA in rats was also observed.

Conclusions: A sustained HS releasing donor consisting of SPRC and DMSN was constructed in this study, and this sustained HS releasing donor might be of good use for the treatment of AIA.

Citing Articles

An Imidazo-Pyridin-Derived Fluorescent Probe for Monitoring Hydrogen Sulfide in Chinese Medicinal Materials.

Mao L, Han X, Wu H, Xu L, Zheng H, Wang F J Fluoresc. 2025; .

PMID: 39903389 DOI: 10.1007/s10895-024-04083-z.

Levamisole Ameliorates Rheumatoid Arthritis by Downregulating the PI3K/Akt Pathway in SD Rats.

Guo M, Yu X, Yang Z, Zheng H, Zhang J, Wang J Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598415 PMC: 11597538. DOI: 10.3390/ph17111504.

New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect.

Zhu M, Ding Q, Lin Z, Fu R, Zhang F, Li Z Biomolecules. 2023; 13(5).

PMID: 37238636 PMC: 10216079. DOI: 10.3390/biom13050766.

Mesoporous Silica-Based Nanoplatforms Are Theranostic Agents for the Treatment of Inflammatory Disorders.

Sivamaruthi B, Thangaleela S, Kesika P, Suganthy N, Chaiyasut C Pharmaceutics. 2023; 15(2).

PMID: 36839761 PMC: 9960588. DOI: 10.3390/pharmaceutics15020439.

Local delivery of gaseous signaling molecules for orthopedic disease therapy.

Sun J, Wang W, Hu X, Zhang X, Zhu C, Hu J J Nanobiotechnology. 2023; 21(1):58.

PMID: 36810201 PMC: 9942085. DOI: 10.1186/s12951-023-01813-6.

References

Assouvie A, Daley-Bauer L, Rousselet G . Growing Murine Bone Marrow-Derived Macrophages. Methods Mol Biol. 2018; 1784:29-33. DOI: 10.1007/978-1-4939-7837-3_3. View

Balas F, Manzano M, Horcajada P, Vallet-Regi M . Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006; 128(25):8116-7. DOI: 10.1021/ja062286z. View

Ray A, Kumar D, Shakya A, Brown C, Cook J, Ray B . Serum amyloid A-activating factor-1 (SAF-1) transgenic mice are prone to develop a severe form of inflammation-induced arthritis. J Immunol. 2004; 173(7):4684-91. DOI: 10.4049/jimmunol.173.7.4684. View

Beltowski J, Jamroz-Wisniewska A . Hydrogen sulfide and endothelium-dependent vasorelaxation. Molecules. 2014; 19(12):21183-99. PMC: 6271169. DOI: 10.3390/molecules191221183. View

Liang Y, Shen Y, Guo W, Zhu Y . SPRC protects hypoxia and re-oxygenation injury by improving rat cardiac contractile function and intracellular calcium handling. Nitric Oxide. 2014; 41:113-9. DOI: 10.1016/j.niox.2014.05.010. View

Huang C, Kan J, Liu X, Ma F, Tran B, Zou Y . Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms. PLoS One. 2013; 8(7):e69205. PMC: 3706411. DOI: 10.1371/journal.pone.0069205. View

Davoli A, Greco V, Spalloni A, Guatteo E, Neri C, Ricciardo Rizzo G . Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. Ann Neurol. 2015; 77(4):697-709. DOI: 10.1002/ana.24372. View

Zheng Y, Zhu J, Ma G, Zhu Q, Yang P, Tan B . Preclinical assessment of the distribution, metabolism, and excretion of S-propargyl-cysteine, a novel H2S donor, in Sprague-Dawley rats. Acta Pharmacol Sin. 2012; 33(6):839-44. PMC: 4010370. DOI: 10.1038/aps.2012.15. View

Udalova I, Mantovani A, Feldmann M . Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016; 12(8):472-85. DOI: 10.1038/nrrheum.2016.91. View

10.

Streng T, Axelsson H, Hedlund P, Andersson D, Jordt S, Bevan S . Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2007; 53(2):391-9. DOI: 10.1016/j.eururo.2007.10.024. View

11.

Pan L, Liu X, Gong Q, Zhu Y . S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanism. Amino Acids. 2011; 41(1):205-15. DOI: 10.1007/s00726-011-0834-1. View

12.

Lopez-Olivo M, Siddhanamatha H, Shea B, Tugwell P, Wells G, Suarez-Almazor M . Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014; (6):CD000957. PMC: 7047041. DOI: 10.1002/14651858.CD000957.pub2. View

13.

Thomas T, Goonewardena S, Majoros I, Kotlyar A, Cao Z, Leroueil P . Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 2011; 63(9):2671-80. PMC: 3168725. DOI: 10.1002/art.30459. View

14.

Tran B, Huang C, Zhang Q, Liu X, Lin S, Liu H . Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction. Biosci Rep. 2015; 35(3). PMC: 4613708. DOI: 10.1042/BSR20140185. View

15.

Tamizhselvi R, Koh Y, Sun J, Zhang H, Bhatia M . Hydrogen sulfide induces ICAM-1 expression and neutrophil adhesion to caerulein-treated pancreatic acinar cells through NF-kappaB and Src-family kinases pathway. Exp Cell Res. 2010; 316(9):1625-36. DOI: 10.1016/j.yexcr.2010.02.044. View

16.

Li L, Liu T, Fu C, Tan L, Meng X, Liu H . Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. Nanomedicine. 2015; 11(8):1915-24. DOI: 10.1016/j.nano.2015.07.004. View

17.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

18.

Wang Q, Wang X, Liu H, Rose P, Zhu Y . Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production. Antioxid Redox Signal. 2009; 12(10):1155-65. DOI: 10.1089/ars.2009.2947. View

19.

Lu M, Liu Y, Goh H, Wang J, Yong Q, Wang R . Hydrogen sulfide inhibits plasma renin activity. J Am Soc Nephrol. 2010; 21(6):993-1002. PMC: 2900962. DOI: 10.1681/ASN.2009090949. View

20.

Ma G, Zhang L, Zhang P, Bao X, Zhou N, Shi Q . Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment. Xenobiotica. 2014; 45(4):322-34. DOI: 10.3109/00498254.2014.980369. View